Exposure | All patients (n=299) | Subgroup aged <70 years (n=219) | Subgroup aged ≥70 years (n=80) |
Bevacizumab dose, n (%) | |||
7.5 mg/kg once every 3 weeks | 289 (97) | 211 (96) | 78 (98) |
15 mg/kg once every 3 weeks | 10 (3) | 8 (4) | 2 (3) |
Bevacizumab duration, months | |||
Median (range) | 10.5 (<0.1–41.4) | 10.6 (<1–29.7) | 10.4 (<1–41.4) |
>12 months, n (%) | 85 (28) | 61 (28) | 24 (30) |
Chemotherapy partner, n (%) | |||
Carboplatin+paclitaxel | 286 (96) | 215 (98) | 71 (89) |
Carboplatin alone | 11 (4) | 2 (1) | 9 (11) |
Other* | 2 (1) | 2 (1) | 0 |
Reason for discontinuing bevacizumab, n (%) | |||
Disease progression | 134 (45) | 95 (43) | 39 (49) |
Adverse event | 35 (12) | 22 (10) | 13 (16) |
Investigator’s decision | 56 (19) | 42 (19) | 14 (18) |
Patient’s decision | 4 (1) | 2 (1) | 2 (3) |
Other | 3 (1) | 2 (1) | 1 (1) |
Completed 18 cycles | 67 (22) | 56 (26) | 11 (14) |
*Carboplatin+doxorubicin (n=1), oxaliplatin+capecitabine (n=1).